(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Lenz Therapeutics's revenue in 2024 is $0.On average, 3 Wall Street analysts forecast LENZ's revenue for 2025 to be $81,914,398, with the lowest LENZ revenue forecast at $33,278,244, and the highest LENZ revenue forecast at $110,150,988. On average, 2 Wall Street analysts forecast LENZ's revenue for 2026 to be $496,677,792, with the lowest LENZ revenue forecast at $469,223,240, and the highest LENZ revenue forecast at $524,132,343.
In 2027, LENZ is forecast to generate $1,191,361,135 in revenue, with the lowest revenue forecast at $1,150,595,286 and the highest revenue forecast at $1,232,126,984.